India, June 29 -- Polyrizon Ltd. (PLRZ), a development-stage biotech company focused on intranasal hydrogels, has received central Institutional Review Board or IRB approval to begin its first human clinical trial for evaluating NASARIX, its nasal spray designed to block airborne allergens.
The approval from the BRANY Institutional Review Board remains valid through June 17, 2027, subject to IRB oversight and regulatory compliance requirements.
The approval confirms that the study protocol, patient consent forms, and trial materials have been reviewed and approved by the central IRB and satisfy applicable ethical and participant protection requirements.
NASARIX is Polyrizon's proprietary nasal spray designed to create a protective barrie...